首页> 美国卫生研究院文献>EXCLI Journal >Why we do what we do. A brief analysis of cancer therapies
【2h】

Why we do what we do. A brief analysis of cancer therapies

机译:为什么我们做我们做的事情。浅析癌症疗法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The goal of all medical activity is to preserve health in fit people, and to restore the sick into a state of complete physical, mental and social wellbeing. In an effort to determine whether we are achieving this last goal in oncology, herein we review the biological and clinical framework that has led to the foundations of the current anticancer treatment paradigm. Currently, cancer therapy is still based on the ancient axiom that states that the complete eradication of the tumor burden is the only way to achieve a cure. This strategy has led to a substantial improvement in survival rates as cancer mortality rates have dropped in an unprecedented way. Despite this progress, more than 9 million people still die from cancer every year, indicating that the current treatment strategy is not leading to a cancer cure, but to a cancer remission, that is “the temporary absence of manifestations of a particular disease”; after months or years of remission, in most patients, cancer will inevitably recur. Our critical analysis indicates that it is time to discuss about the new key challenges and future directions in clinical oncology. We need to generate novel treatment strategies more suited to the current clinical reality.
机译:所有医疗活动的目标是保持健康人的健康,并将生病恢复为完全的身体,心理和社会福祉状态。努力确定我们是否在肿瘤学中达到这一目标,在此审查了导致目前抗癌治疗范式的基础的生物学和临床框架。目前,癌症疗法仍然基于古代公理,使得完全根除肿瘤负担是实现治愈的唯一方法。由于癌症死亡率以前所未有的方式降低,这种策略导致生存率的大量改善。尽管这一进展,每年超过900万人仍然死于癌症,表明目前的治疗策略并未导致癌症治愈,而是对癌症缓解,即“暂时没有特定疾病的表现形式”;经过数月或多年的缓解,在大多数患者中,癌症将不可避免地重复。我们的关键分析表明,是时候讨论了临床肿瘤学中的新关键挑战和未来方向的时候了。我们需要产生更适合目前临床现实的新型治疗策略。

著录项

  • 期刊名称 EXCLI Journal
  • 作者

    Carlos M. Galmarini;

  • 作者单位
  • 年(卷),期 2020(-1),-1
  • 年度 2020
  • 页码 -1
  • 总页数 13
  • 原文格式 PDF
  • 正文语种
  • 中图分类
  • 关键词

    机译:肿瘤;分子靶向疗法;免疫疗法;人工智能;抗血管生成剂;
  • 入库时间 2022-08-21 12:08:04

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号